Aclarion (NASDAQ:ACON) & Pheton (NASDAQ:PTHL) Critical Contrast

Aclarion (NASDAQ:ACON) and Pheton (NASDAQ:PTHL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Institutional and Insider Ownership

7.5% of Aclarion shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Aclarion and Pheton, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Pheton	1	0	0	0	1.00

Aclarion currently has a consensus price target of $7.50, indicating a potential upside of 176.75%. Given Aclarion’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Aclarion is more favorable than Pheton.

Earnings and Valuation

This table compares Aclarion and Pheton”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	97.56	-$7.23 million	($7.40)	-0.37
Pheton	$305,215.00	6.29	-$660,000.00	N/A	N/A

Pheton has higher revenue and earnings than Aclarion.

Volatility and Risk

Aclarion has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Pheton has a beta of 5.4, suggesting that its stock price is 440% more volatile than the S&P 500.

Profitability

This table compares Aclarion and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Pheton	N/A	N/A	N/A

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.